Palo Alto, CA – April 27, 2021– A&P Inphatec, a specialist developer of bacteriophages, announced today the release of important new field trial data on the efficacy of XylPhi-PD™, the biologically based reduction of Pierce’s Disease (PD) in grapevines. XylPhi-PD™ is OMRI-listed and approved for use in organic production.
XylPhi-PD™ (EPA Reg. No. 93909-1) is registered for use in California and is commercially available through Wilbur-Ellis Agribusiness locations State-wide.
The first in-depth public presentation of this new data is scheduled on May 4th at the upcoming EnoForum USA Technical Conference by Dr. Anika Kinkhabwala (Principal Scientist, A&P Inphatec) and Dr. Carlos F. Gonzalez (Texas A&M AgriLife Research Professor, Plant Pathology and Microbiology, Texas A&M University, College of Agriculture and Life Sciences).
The post A&P Inphatec Announces 2020 Field Trial Efficacy Results for XylPhi-PD™ appeared first on Wine Industry Advisor.